Please login to the form below

Not currently logged in
Email:
Password:

ABPI/ BIA relocate together

The UK's Association of the British Pharmaceutical Industry and the BioIndustry Association are to relocate to shared offices in London by the end of May

The UK's Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) are to relocate to shared offices in the Victoria region of London by the end of May.

The bodies, each representing its respective area of life sciences, will remain independent organisations, although the move will 'faciliate more effective joint working on cross-industry issues' according to a shared statement.

Announcing the move, Dr Richard Barker, director general of the ABPI, commented on increased collaborative efforts with the BIA since the establishment of the UK Office for Life Sciences in April 2009 to address key issues affecting the pharmaceutical, medical biotech and devices sectors.

He said: "Our organisations have been able to operate more strategically, and more effectively, by representing the life sciences sector with one voice, alongside the ABHI [Association of British Healthcare Industries] and BIVDA [British In Vitro Diagnostics Association]. This move strengthens a joint determination that the UK remain a great place to invest and do business in life sciences."

Nigel Gaymond, chief executive of the BIA, also championed the decision: "The UK has exceptional strengths in life sciences. Establishing a central venue where those with an interest in life sciences can access the combined expertise of the BIA and ABPI will enable us to highlight more effectively all that the UK has to offer."

16th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
foxandcat.online

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

Virtual meeting technologies for reducing emissions and waste in the healthcare industry
...
Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...